Angeliki Befon

Athens, ESYE31, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: May 05, 2026

Divergent pathways of melanoma development: evidence from a Southern European cohort.

Divergent pathways of melanoma development: evidence from a Southern European cohort.

Journal: Melanoma research

Published: September 08, 2025

Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in patients with plaque psoriasis: results from a real-world multicentre study.

Long-term effectiveness, safety and prognostic factors of response to treatment with bimekizumab in patients with plaque psoriasis: results from a real-world multicentre study.

Journal: Clinical and experimental dermatology

Published: May 12, 2025

Bimekizumab Treatment for Scalp Psoriasis: A 52-Week, Real-World, Retrospective Study.

Bimekizumab Treatment for Scalp Psoriasis: A 52-Week, Real-World, Retrospective Study.

Journal: International journal of dermatology

Published: November 21, 2024

Number of melanoma deaths over time in relation to tumour thickness: Data from a Melanoma Unit Reference Center.

Number of melanoma deaths over time in relation to tumour thickness: Data from a Melanoma Unit Reference Center.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 06, 2024

Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.

Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.

Journal: Archives of dermatological research

Published: July 20, 2024

Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areas.

Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areas.

Journal: International journal of dermatology

Published: April 09, 2024

Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis.

Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 26, 2023

Targeted sequencing analysis of loci implicated in familial melanoma in a Greek cohort.

Targeted sequencing analysis of loci implicated in familial melanoma in a Greek cohort.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 05, 2023

Subungual melanoma: the experience of a Greek melanoma reference centre from 2003 to 2018.

Subungual melanoma: the experience of a Greek melanoma reference centre from 2003 to 2018.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: January 17, 2020

Serum Total 25-Hydroxyvitamin D Levels in Patients With Cutaneous Malignant Melanoma: A Case-Control Study in a Low-Risk Southern European Population.

Serum Total 25-Hydroxyvitamin D Levels in Patients With Cutaneous Malignant Melanoma: A Case-Control Study in a Low-Risk Southern European Population.

Journal: Dermatology practical & conceptual

Published: September 24, 2019

Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.

Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 12, 2019

Showing 1-12 of 14

Last Updated: 09/26/2026